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Oxidative stress is defined as an imbalance beween the levels of reactive oxygen species 
(ROS) and antioxidant defences. The view of oxidative stress as a cause of cell damage has 
evolved over the past few decades to a much more nuanced view of the role of oxidative 
changes in cell physiology. This is no more evident than in the field of immunity, where 
oxidative changes are now known to regulate many aspects of the immune response, and 
inflammatory pathways in particular. Our understanding of redox regulation of immunity 
now encompasses not only increases in   reactive oxygen and nitrogen species, but also 
changes in the activities of oxidoreductase enzymes. These enzymes are important 
regulators of immune pathways both via changes in their redox activity, but also via other 
more recently identified cytokine-like functions. The emerging picture of redox regulation of 
immune pathways is one of increasing complexity and while therapeutic targeting of the 
redox environment to treat inflammatory disease is a possibility, any such strategy is likely 
to be more nuanced than simply inhibiting ROS production.   
 
1. Introduction 
Inflammatory disease is often associated with oxidative changes.  Some of the earliest 
reports in terms of the biochemical mechanisms involved were the identification of 
arachidonic acid oxidation products [1] and the inhibitory effects of antioxidants on the 
production of prostaglandins and thromboxanes [2]. These findings were based on even 
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earlier studies on rancidification of lipids in food and, were similarly measured by following 
the formation of malondialdehyde (MDA), also defined as thiobarbituric acid-reactive 
substance [3, 4].  
A second aspect is that reactive oxygen species (ROS) produced by neutrophils during the 
oxidative burst to kill bacteria [5] can cause collateral damage and inflammation [6]. 
Pioneering studies by McCord have also implicated ROS in postischemic tissue injury [7], 
thus broadening the list of diseases for which oxidative stress is implicated. This prompted 
the hypothesis that low-molecular weight antioxidants [8], as well as antioxidant enzymes 
[9], could ameliorate inflammatory and immune-mediated disease. 
With the discovery of inflammatory cytokines in the 1980s [10, 11] and the success of the 
cytokine theory of disease with the approval of anti-TNF antibodies for the treatment of 
rheumatoid arthritis and Crohn’s disease, it was only natural that researchers investigated 
the effect of antioxidants and oxidants on cytokine production. We reported that 
endogenous glutathione (GSH) is an inhibitor of TNF production [12], a study that was 
followed by others showing inhibitory effects of antioxidants on inflammatory cytokine 
production [13]. 
However, a molecular mechanism for this effect was clarified only in the early 1990s in the 
laboratory of Patrick Baeuerle, with the finding that antioxidants inhibit, and ROS activate, 
the transcription factor NF-kB, which is involved in the transcription of many inflammatory 
genes, including cytokines [14, 15]. 
 
2. From the concept of oxidative stress to those of redox regulation and eustress 
NF-κB was first described in 1986 as a transcription factor acting on immunoglobulin genes 
in B cells [16]. The first connection with inflammation was the discovery that TNF activates 
NF-κB [17]. Later, it was found that NF-κB activates the transcription of TNF [18] and other 
cytokines [19] in response to inflammatory stimuli. NF-κB entered the redox arena in 1991 
with a paper from Baeuerle’s lab which showed for the first time that NF-κB is activated by 
H2O2 and its activation by inflammatory stimuli is inhibited by thiol containing compounds 
including N-acetylcysteine [14]. This paper has since been cited over 4100 times. This study 
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raised the important point that apparently ROS can function exclusively as second 
messengers only in a narrow range of concentrations, while at higher concentrations are 
mainly toxic [14]. 
 
3. Molecular mechanisms of redox regulation: the role of protein thiols 
The seminal study by Schreck et al. [14] describing the effects of ROS on activation of NF-κB 
did not attempt to investigate the mechanism by which NF-κB is redox regulated; the 
mechanism by which NF-κB is redox regulated was simply depicted by an arrow with no 
further detail given. We will focus here on oxidoreduction of cysteine residues in proteins, in 
particular to form intramolecular disulfides or mixed disulfides with glutathione (protein 
glutathionylation). 
In fact, while the classical explanation found in textbooks is that protein cysteines can exist 
in two forms, either as free thiols or engaged in a structural disulfide to hold together the 
3D structure of the protein, there are many more forms of cysteine oxidation. Those that 
are reversible are clear candidates for redox regulatory mechanisms. The essence of this 
aspect of redox regulation is that these post-translational modifications can regulate protein 
activity. Figure 1 outlines two examples of cysteine oxidation: formation of intra-protein 
disulfide and glutathionylation, together with the similarities to the well-known regulatory 




Figure 1. Regulation of protein function by cysteine oxidation. A) Formation of reversible intraprotein 
disulfides non-enzymatically or by direct oxidation with GSH or thiol-disulfide exchange with GSSG. The panel 
also depicts the oxidation of a thiol by the action of ROS (the figure depicts the formation of a sulfenic 
acid,but it could also be a sulfinic (–SO2H) or sulfonic(–SO3H) acid. B) glutathionylation where mixed 
disulfides are formed between a cysteine residue in a protein and GSH. C) alteration of protein activity by 
phosphorylation catalyzed by kinases or phosphatases.  
 
Protein cysteines can also be S-nitrosylated by reactive nitrogen species or oxidized by ROS 
to form sulfenic, sulfinic or sulfonic  acids. Oxidation to sulfinic and sulfenic acid is reversible 
[20] and may thus have regulatory roles.  Enzymes of the family of the protein thiol-disulfide 
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oxidoreductase (PDOR), such as thioredoxin (Trx), glutaredoxin (Grx), Quescin-sulfhydryl 
oxidase (Qsox), or sulfiredoxin (Srx) can catalyze the oxidoreduction of protein thiols and 
disulfides in either direction, depending on the redox environment [21-23] 
One of the first examples of a protein involved in inflammation that can be regulated by 
formation of an intramolecular disulfide is Keap-1 [24], resulting in activation of the 
transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2; as discussed below). 
Among the first proteins reported to undergo glutathionylation was the p50 subunit of NF-
κB, as well as others of pivotal importance in regulating the inflammatory response. The top 
half of Table 1 lists some examples of proteins relevant to inflammation that are subject to 
regulation by different forms of cysteine oxidation. 
Table 1. Key redox regulated proteins in immunity 
Reversible disulfide formation 
Modification Target 
cysteine(s) 












C54, C347 NEMO Dimerization, IKK binding [25] 
S-
glutathionylation 
? p50 DNA binding [26] 
S-
glutathionylation 
? STAT3 DNA and Jak2 binding [27] 
S-
glutathionylation 
C91 MAL Interaction with Myd88 [28] 
Other reversible forms of oxidation 
















Although this discussion of molecular mechanisms focuses on protein thiol-disulfides and 
glutathionylation, other forms of protein oxidation have been shown to regulate 
inflammation, the most important of which are listed in the lower half of Table 1.  
Methionine oxidation to methionine sulfoxide has long been known to inactivate alpha-1 
proteinase inhibitor (alpha-1-antitrypsin) [29], as well as other proteins relevant in 
inflammation and immunity such as interferons and chemotactic peptides (reviewed in 
[33]). This oxidation is reversed by methionine sulfoxide reductase that reactivates the 
target protein [34]. 
It should be noted that most cysteines that are susceptible to glutathionylation can also 
undergo S-nitrosylation or cysteinylation as shown below: 
S-nitrosylation: P-SH +XNO -> PSNO 
S-cysteinylation: P-SH + Cys-SH -> P-s-s-Cys 
 There are examples of both of these post-translational oxidative changes in regulating 
immune function. S-nitrosylation targets many proteins in the immune system [35] such as 
surfactant proteins [31], innate immune receptors such as NLRP3 (Mishra et al., 2012; Mao 
et al., 2013) and signaling molecules such as MyD88 (Into et al., 2008) which is important in 
inflammatory signaling downstream of Toll-like receptors. Cysteinylation can occur during 
processing of peptide ligands for presentation on MHC molecules thereby affecting antigen 
processing and presentation to T cells [32]. 
Another aspect to be taken into account is that not all cysteines in a protein are equally 
susceptible to oxidative post-translational modifications. This is determined by several 
factors including the pK value of the cysteine, which is affected by the neigbouring 
aminoacids as well as its steric accessibility, particularly in the case of glutathionylation 




4. The immuno-regulatory roles of protein thiol-disulfide oxidoreductases 
Protein thiol-disulfide oxidoreductases (PDORs) are enzymes that catalyze the 
oxidoreduction of protein thiols and disulfides as described above. There are a number of 
PDORs with different and some overlapping functions. Table 2 lists the main mammalian 
PDORs. 
Table 2. Main mammalian protein thiol-disulfide oxidoreductases. 




Grx Mainly a reductant. Reduction of PSSG to PSH. 
Needs glutathione reductase and NADPH. 
PSSG -> PSH + GSH 
Thioredoxin Trx, 
Txn 
Mainly a reductant. Generic reduction of protein 
disulfides. Needs Trx reductase and NADPH. 
PSSP -> PSH 
Peroxiredoxin Prdx Prdxs are thioredoxin peroxidases, and catalyze the 
reduction of H2O2 to water using reduced Trx as the 
electron donor. 
H2O2 + Trx-(SH)2 -> H2O + Trx-(SS) 
Protein disulfide 
isomerase 
PDI Mainly an oxidant. Oxidation of protein thiols to 
form structural disulfides. 
PSH + GSSG -> PSS + GSH 
Sulfiredoxin Srx Reductant. Reduces Prdx oxidized to sulfinic acid 
using ATP and a thiol as electron donor; also 
reduces glutathionylated proteins. 
PSOH + XSH + ATP -> PSH + XSSX + ADP 
Quiescin-sulfhydryl 
oxidase 
Qsox Oxidizes protein thiols to disulfides by 
concomitantly reducing O2 to H2O2. 
PSH + O2 -> PSS + H2O2 
PSH, protein thiol; PSSP, protein disulfide; PSSG, protein-GSH mixed disulfide 
 
5. Activities of extracellular protein thiol-disulfide oxidoreductases 
There are many lines of evidence demonstrating the involvement of intracellular PDORs in 
the intracellular signaling pathways downstream of activated pattern recognition receptors 
on innate immune cells. One of the best examples of this are the Toll-like receptors (TLRs) 
that, upon recognition of PAMPs or DAMPs, initiate complex intracellular signaling cascades 
that culminate in activation of the transcription factors AP1 and NF-KB. Once activated, 
these transcription factors drive the expression of genes coding for cytokines and other pro-
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inflammatory proteins. PDORs play important roles at various points in these signaling 
pathways as shown in Fig. 2 and reviewed in [37, 38] . It is important to note that the effects 
of the PDORs in these signaling pathways are reliant on their oxidoreductase activity and 
not simply due to non-enzymatic effects of these proteins. Thus, changes in the redox states 
of these enzymes can result in dissociation of molecules that, once released from their 
associations, can participate in downstream signaling to facilitate changes in gene 
expression. These redox changes can be viewed as another form of post-translational 






Fig. 2. Regulation of inflammatory signaling pathways by PDORs. Activation of cell-surface located TLRs by 
pathogen associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) triggers 
an intracellular signaling pathway that leads to transcription of cytokines, chemokines and other proteins 
involved in inflammatory responses. Activation of TLRs results in activation of mitogen-activated protein kinase 
kinase (MAPKK) and dissociation and degradation of inhibitor of kappa B (iKB) resulting in activation of the 
transcription factors AP-1 (activator protein -1) and NF-κB (shown here as the p65 and p50 subunits) 
respectively. The signaling pathway downstream of TLR activation is reliant on sequential phosphorylation of 
various signaling molecules (shown here by the P in the upper right of the protein name). The points in these 
signaling pathways that are regulated by PDORs are indicated by the names of the PDORs involved, together 
with the effect of each enzyme of the activity of the target signaling molecule. Nrx: nucleoredoxin is a Trx-
related enzyme. Modified from [37] (CC BY 4.0). Additional abbreviations: activator protein 1 (AP-1); apoptosis 
signal-regulating kinase 1 (ASK1); c-Jun N-terminal kinase (JNK); damage-associated molecular patterns 
(DAMP);  DD loop (DD); IκB kinase (IKK);  interleukin-1 receptor-associated kinase (IRAK); myeloid 
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differentiation primary response 88 (MYD88); pathogen-associated molecular patterns (PAMP); redox factor-1 
(Ref1); Toll-IL-1-receptor  domain (TIR); tumor necrosis factor receptor-associated factor (TRAF). 
 
Although PDORs are intracellular enzymes, some of them are secreted under various 
physiological conditions. However, PDORs may not be enzymatically active in the 
extracellular environment due to a lack of necessary cofactors (e.g. Trx requires Trx 
reductase and NADPH; Prdx requires Trx, Trx reductase and NADPH; Grx requires GSH) but 
have been reported to have cytokine-like activities. In some cases, these activities were 
described before identifying the hypothetical cytokine as a PDOR. These activities are listed 
in Table 3. 
 
Table 3. Biological activities of secreted PDORs 
Enzyme Alternative names Extracellular actions Reference 
Trx Adult T-cell leukemia-
derived factor (ADF) 
T-cell proliferation and 
activation 
[39, 40] 




enhancing factor (ECEF) 
Increases antibody-dependent 
cytotoxicity of eosinophils 
[43] 
Prdx (NK) cell enhancing factor 
(NKEF) 
NK cell activation [44] 
Prdx  Induce inflammatory 
cytokines 
[45, 46] 
PDI  Thrombus formation; beta 2 
integrin regulation 
[47] [48]s 




Probably the best such example is represented by Trx. This enzyme was discovered by Arne 
Holmgren as the intracellular enzyme serving as an essential cofactor of ribonucleotide 
reductase (reviewed in:  [50]), and its sequence was determined in 1968 [51]. Years later, in 
1985, the laboratory of virologist Junji Yodoi characterized a cytokine produced by adult T-
cell leukemia cells that upregulates the expression of interleukin 2 receptor in T cells, and 
named it adult T-cell leukemia-derived factor (ADF) [39]. Once the protein was sequenced, 
four years later, it was found to be identical to Trx [52]. 
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Since then, various other activities of extracellular Trx have been described, most notably as 
a chemotactic factor [42] and, in its truncated form (Trx80), as a monocyte activator [53, 
54]. In addition, extracellular Trx released by antigen-presenting cells generates small-
molecular weight thiols via it enzyme action that contribute to T cell activation [55]. 
Germane to this story, researchers purified a cytokine that stimulated eosinophil antibody-
dependent cytotoxic function, and found that the purified protein was identical to Trx [43].  
More recently, Prdxs have been reported to be secreted and act as pro-inflammatory agents 
[45, 56] possibly through activation of Toll-like receptors [57]. 
 
6. Redox regulation of signaling molecules  
The pioneering studies on NF-κB mentioned above were the first demonstration of redox 
regulation of a specific protein in an inflammatory signaling pathway. As indicated in Table 
1, several elements of the inflammatory signaling pathway are redox regulated via 
glutathionylation. Interestingly, earlier ideas  of how oxidative stress mediates the induction 
or maintenance of inflammation, viewed glutathione mainly as an antioxidant and free 
radical scavenger that would inhibit inflammation (see for instance our earlier studies [12, 
58]). However, within the concept of redox regulation glutathione can be seen as a signaling 
molecule, similar to ATP which is not only an energy-storage molecule but, through protein 
phosphorylation, is also essential in cellular signaling [59]s.  We recently described how 
macrophages depleted of GSH do not show a full response to endotoxin in terms of 
activation of gene expression profile [60]. If GSH was acting mainly as an inhibitor of ROS-
mediated activation of inflammatory pathways, we would expect its depletion to exacerbate 
the response to endotoxin. However, we found that there were more inflammation-induced 
genes that require GSH for full induction [60]. While GSH may participate in redox regulation 
in different ways, protein glutathionylation is one of the most studied mechanisms. 
To obtain a list of the genes involved in innate immunity that were reported to undergo 
glutathionylation, we performed a literature search on August 9, 2019, searching for 
“glutathionylation or glutathionylated” and each of the 849 in the Gene Ontology term 
”innate immune response” (GO:0045087) and the 1326 in the Gene Ontology term 
“inflammatory response” (GO:0006954). The search returned 967 publications and abstracts 
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were read to identify the proteins reported to undergo glutathionylation. Those not related 
in any way to inflammation or immunity were excluded. The final list of 41 genes were (by 
official gene symbol): ALOX5, CASP1, CASP8, CSTA, CYPA, CYPD, DUSP1, ENOS, FAS, GAPDH, 
IKBKB, IL1B, IL1SRII, ITGA4, JAK1, JAK2, MAL/TIRAP, NCF1, NFKB, NLRP3, NOS3, P47PHOX, 
PFN1, PON1, PP2A, PRDX1, PRDX2, PTEN, RELA, S100A8, S100A9, SERPINA1, SIRT3, STAT1, 
STAT3, THOP1, TP53, TRAF3, TRAF6, TTR, TXN1, VIM. For many of these proteins, 
glutathionylation can affect their activity, as in the case of STAT3 (see Table 1).This indicates 
that redox regulation may occur at several steps in the immune signalling pathways. 
We have analyzed the list of genes above using the reactome analysis tool [61, 62], to 
highlight specific innate immune signalling pathways susceptible to redox regulation.  The 
results of this analysis are shown in Figure 3, which highlights the signalling pathways 
involved in the activation of inflammatory signalling where regulation by glutathionylation is 
involved. Several interleukin signalling pathways (left side of the figure) are 





Fig. 3. Pathways overrepresented by the 41 proteins susceptible to glutathionylation. A Voronoi map obtained 
with Reactome (www.reactome.org; refs. [61, 62] is shown relative to the pathway “immune system”. Colour 
indicates P value for over-representation (colour code is provided on the bottom left: dark yellow 0.05, light 
yellow 0). Key signalling pathways have been labelled manually due to the poor resolution of the software-
generated image. Abbreviations used: Interleukin (IL); interferon alpha (IFNA); interferon gamma (IFNG); NOD-
like receptor (NLR); Shc adaptor protein (SHC); Toll-like receptors (TLRs). 
 
7. ROS and activation of the NLRP3 inflammasome 
 
The nucleotide-binding oligomerization domain (NOD)-like receptor containing pyrin domain 
3 (NLRP3) inflammasome that is necessary for intracellular processing of pro-IL-1β and 
secretion of active IL-1β [63]s was first described by Martinon et al [64]s. This was an 
important discovery as it led to greater understanding of how IL-1β, a pro-inflammatory 
cytokine heavily implicated in inflammatory diseases such as RA, gout and cardiovascular 
disease, is produced and secreted during innate immune responses. Since then, numerous 
studies have investigated the importance of ROS in NLRP3 activation. The potential role of 
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ROS in NLRP3 activation stemmed from early studies demonstrating that inhibition of 
NADPH oxidase enzymes by diphenyleneiodonium (DPI) reduced IL-1β secretion in alveolar 
macrophages or primary human monocytes [65-67]. This was confirmed by knock-down of 
NADPH oxidase p22phox subunits which resulted in inhibition of IL-1β secretion in response to 
monosodium urate (MSU) crystals or asbestos[66]. Together, these data strongly suggested 
that NADPH oxidase-induced ROS production was critical for activation of NLRP3. However, 
the necessity of ROS generated by NADPH oxidases for activation of NLRP3 has since been 
disputed by studies using mononuclear cells from patients with CGD, an immunodeficiency 
disease caused by defects in phagocyte NADPH oxidase subunits. MSU and silica induced IL-
1β secretion in these cells was unaffected despite the loss of NADPH oxidase induced ROS 
[68-70]. Mitochondria[71-73] and xanthine oxidase[74, 75] have since emerged as 
important sources of ROS in activating NLRP3 but there are also several studies that 
contradict the hypothesis that ROS are necessary for NLRP3 activation and secretion of IL-
1β[76, 77]. Therefore, the exact role of ROS in activating NLRP3 remains a matter of debate, 
with numerous studies showing conflicting results as summarized in Table 3. It is likely that, 
like any mechanistic hypothesis, this cannot be generalized and only applies to specific 
experimental models. 
Thus, the current understanding of the role of ROS in NLRP3 activation is unclear and likely 
involves other strands of redox regulation rather than ROS levels in isolation. A number of 
elements of the redox regulatory machinery have been shown to be involved in activation of 
NLRP3 including the antioxidant enzyme SOD1[78], glutathionylation of caspase-1 via 
increased superoxide levels[79] and activation of Nrf2 resulting in transcription of 
glutathione, thioredoxin and other antioxidants such as NADPH dehydrogenase 1 and 
heme[80, 81]. This hypothesis posits that redox modulation, rather than simply ROS levels, 
is the important factor in IL-1β processing[82] and provides a possible explanation for the 
evidence both for and against the involvement of ROS in NLRP3 activation. Furthermore, a 
wide array of structurally diverse NLRP3 activators have been identified (in addition to MSU 
crystals), including viral RNA, components of microbial cell walls, nucleic acid, pore-forming 
toxins, silica, asbestos, ATP and serum amyloid A.  The diversity of these molecules make it 
likely that NLRP3 is not activated by direct interaction with these stimuli, rather by a 







Table 4. Evidence for and against a role for ROS in activation of the NLRP3 inflammasome 







Treatment of cells with ATP induces ROS. Inhibition of NADPH-
oxidase derived ROS by DPI reduced ATP-induced caspase-1 
activation and IL-1β production 
For 2007 [65] 
THP-1 cells 
Knockdown of p22phox subunit of NADPH-oxidase supressed 
IL-1β release in THP-1 cells in response to asbestos and MSU 
For 2008 [66] 
THP-1 cells 
Extracellular ATP causes NADPH-oxidase induced oxidation 
and IL-1β secretion in THP-1 cells.  Treatment with NAC and 
DPI inhibited caspase-1 processing in response to extracellular 
ATP 
For 2004 [67] 
THP-1 cells 
Inhibition of mitochondrial complex I induced ROS production 
which correlated closely with NLRP3-dependant IL-1β 
secretion. Inhibition of mitochondrial respiration abrogated IL-
1β production and caspase-1 activation 
For 2011 [73] 
Alveolar 
macrophages 
Inhibition of mitochondrial ROS by SS-31 dose-dependently 
inhibited cyclic stretch induced capase-1 activation and IL-1β 
production 





Mitochondrial dysfunction is linked to NLRP3 activation and 
mitochondrial DNA is required for NLRP3 inflammasome-
mediated IL-1β secretion 




Redox regulated TXNIP binds directly to NLRP3 in response to 
MSU exposure. siRNA blocking of TXNIP expression abrogated 
caspase-1 activation and IL-1β secretion 
For 2010 [85] 
Human 
PBMCs 
IL-1β secretion is ROS-dependant but in an NADPH-oxidase-
independent manner. Cells from p22phox- and NOX2-deficient 
patients had normal IL-1β secretion 
Both 2010 [69] 
Human 
monocytes 
IL-1β secretion is normal in mononuclear cells from patients 
with chronic granulomatous disease (CGD), a disease 
characterised by defective NADPH-oxidase enzymes 
Against 2010 [68] 
Human 
monocytes 
NLRP3 can be activated in a ROS-independent manner in 
monocytes from patients with CGD. Inhibition of ROS with DPI 
did not decrease caspase-1 activation or secretion of IL-1β in 
cells from these patients 
Against 2010 [70] 
Murine 
macrophages 
Elevated ROS in SOD1-deficient mouse macrophages inhibited 
caspase-1 activation. This could be reversed dose-dependently 
with SOD-mimetics which caused increased ATP-induced IL-1β 
secretion 
Against 2008 [79] 
Murine 
BMDMs 
Nrf2, a redox sensitive transcription factor for a range of 
antioxidant genes, is essential for inflammasome activation 
and IL-1β secretion in response to cholesterol 
Against 2011 [80] 
Murine 
BMDMs 
IL-1β secretion in TXNIP-deficient macrophages secreted 
normal levels of IL-1β compared to wild-type macrophages in 
response to MSU, ATP and islet amyloid polypeptide 
Against 2010 [86] 
Murine 
macrophages 
Inhibition of ROS by DPI and NAC inhibited NLRP3 priming but 
not activation. Only had an effect when cells were 
preincubated with ROS inhibitors prior to activation 





8. Redox mechanisms that affect macrophage polarization in the context of chronic 
inflammation 
Macrophages are extremely plastic cells that play a central role in inflammation and its 
resolution [89]. The ontogeny, the tissue-specific environment and altered homeostasis at 
the site of injury, including signals generated by TLR ligands, such as microbial products or 
danger-associated molecular patterns (DAMPs), are all involved in causing phenotypic and 
functional changes [90, 91]. Macrophages can be broadly classified into M1 and M2 
subtypes [89, 91, 92]. M1 have microbicidal functions and are considered pro-inflammatory 
whereas M2 promote cell proliferation and contribute to wound healing. M1 respond to TLR 
agonists and to IFN- produced by Th1 cells by activating iNOS and producing NO and ROS to 
kill pathogens, and secrete pro-inflammatory cytokines, such as IL-8, TNF and IL-1and IL-
12 that drives Th1 responses. M2 express high levels of arginase that hydrolyses arginine to 
ornithine, essential for collagen synthesis and cell proliferation, thus favouring tissue repair 
and regeneration; they generally produce TGF- and IL-10 that sustain Th2 responses, and 
may have anti-inflammatory functions [93-95]. M1 and M2 macrophages are also 
characterised by different metabolism; M2 rely on mitochondrial oxidative phosphorylation 
for energy production, whereas M1 are preferentially glycolytic [96-98].  
Although M1 and M2 macrophages represent the extremes of a spectrum of different 
functional subsets described in vitro and not necessarily present in vivo, it is accepted that 
an immune response broadly skewed towards M1 (and Th1) polarization may be involved in 
the pathogenesis of chronic inflammatory disease [89, 99], and greater knowledge of the 
mechanisms that differentiate M1 from M2 and drive M2 polarization might be exploited 
for therapeutic purposes.  
All the different M1 and M2 functions are driven by a variety of transcription factors. M1 
macrophages mainly express STAT1, NF-kB, IRF5 and AP-1, whereas STAT6, PPAR- and IRF4 
are predominantly expressed in M2 [91]. HIF-1 is highly expressed in M1 and coordinates 
glycolytic metabolism and pro-inflammatory cytokine production whereas PPAR- in M2 
mediates fatty acid oxidation and mitochondrial oxidative phosphorylation [96, 97, 100]. 
Interestingly, most of these transcription factors (e.g. HIF-1, NF-kB, STAT6, PPAR- are 
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redox targets [14, 101-104]. Some specific redox mechanisms that regulate M1 and M2 
polarization by affecting pro-inflammatory cytokine production, cell metabolism and/or 
transcription factor activation are described below.  
ROS have been shown to increase pro-inflammatory cytokine production, and therefore M1 
polarization, by potentiating LPS-induced MAPK activation [105, 106]; a mechanism might 
be inhibition of MAPK phosphatases, redox targets that can be inactivated by reversible 
(and irreversible) oxidation of their catalytic cysteine [107-109]}. Also NF-kB can act as a 
redox switch to increase M1; in microglia oxidation of the NF-kB p50 subunit by H2O2 
decreases its binding to DNA and increases pro-inflammatory cytokine production and 
M1/M2 balance [102], confirming the predominant inhibitory role of NF-kB p50 on M1 
polarization [110]. In addition, extensive literature has linked ROS to activation of the 
inflammasome, required for production of mature IL-1highly expressed in M1 
macrophages [65-67, 71-73]. However, as discussed above, investigation of the role of ROS 
on the activation of the inflammasome has produced controversial results (Table 4). 
Many redox intracellular targets may be responsible for the impact of ROS on cell 
metabolism. Mitochondrial oxidative phosphorylation can be inhibited through S-
glutathionylation, mediated by Grx2, of complex I of the mitochondrial respiratory chain 
[111]. In addition, ROS can increase glycolysis by augmenting HIF-1 stabilisation and glucose 
uptake. In this respect, HIF can be stabilised in normoxia following inactivation of prolyl 
hydroxylase domain enzymes (PHDs), responsible for targeting HIF- subunits to the 
proteasome; inhibition of their activity is due to oxidation of cysteines in the active site 
[101]. Glucose uptake can be increased by H2O2-induced phosphorylation of AMPK and Akt, 
mediating translocation of the main glucose transporter GLUT4 to the plasma membrane 
[112]. Inhibition of phosphatases by ROS, also mentioned above, might explain the 
increased phosphorylation of AMP and Akt [107, 108]. Decreased oxidative phosphorylation 
and increased glycolysis will result in increased M1 polarization. 
All the above evidence points to the possibility that inhibiting ROS might inhibit M1 and 
induce M2 polarization. However, ROS are also required for induction of M2 polarization, as 
shown in human and murine macrophages and in vivo in mice [103, 113, 114]. Interestingly, 
in mice with pulmonary fibrosis H2O2 produced by SOD1 enhanced M2 polarization by 
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increasing the transcriptional activity of STAT6, due to redox regulation of a cysteine in its 
Src homology domain 2 [103]. 
The fact that ROS may play a role in resolution of inflammation is also supported by the 
observation that individuals with CGD, characterized by the lack of NOX2-mediated ROS 
production, in addition to increased infections exhibit also hyperinflammatory responses 
and an increased frequency of autoimmune disease [115, 116] . Also, polymorphisms 
affecting Ncf1, the p47 subunit of NOX2, resulting in lower production of ROS, are 
associated with many autoimmune chronic inflammatory disorders [117], suggesting that 
ROS might inhibit chronic inflammation.  Transgenic rescue of Ncf1 in mononuclear 
phagocytes of Ncf1-mutant mice inhibited hyperinflammation, demonstrating that ROS 
produced by NOX2 in macrophages are required for resolution of inflammation [118]. In 
addition, it is interesting to note that Weyand et al reported in a series of studies that T cells 
from RA patients are ROS-deficient, due to a shift in metabolism; glycolysis is inhibited and 
glucose is diverted into the pentose phosphate pathway (PPP), resulting in production of 
lower levels of intracellular ROS and excessive NADPH [119-121]. This “reductive stress” 
correlates with an inflammatory phenotype and Th1/Th17 polarization, which can be 
reverted by treatment with oxidants [122]. 
Although there is evidence that ROS support M1 polarization and a pro-inflammatory 
response [97, 102, 104, 111], paradoxically ROS-deficiency can result in chronic 
inflammation. Thus, ROS also seem to favour M2 polarization and resolution of 
inflammation. A possible mechanism might be through induction of NRF2 [104]. In this 
regard, recent data have shown that NRF2 activation can enhance M2 polarization [123-
126]. It could also be predicted that decreased physiological ROS levels might prevent 
feedback induction of NRF2, resulting in amplification of the M1 response. 
There many studies that describe how changes in the redox extracellular and intracellular 
environment and redox modifications of transcription factors and signalling molecules can 
shape the immune response by driving functional changes in macrophages. However, 
contrasting evidence makes it difficult to reach firm conclusions and to identify redox 
therapeutic targets [90, 98, 104, 127]. 
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9. Redox regulation in inflammatory disease 
The association of inflammation with oxidative stress and vice versa has been recognized for 
decades and is perhaps unsurprising given the intimate links between aspects of innate 
immunity, for example the oxidative burst in neutrophils, and ROS levels. However, it has 
proved difficult to fully elucidate the exact relationship between increases in oxidative stress 
and inflammation and in particular to determine the extent to which this is a causal 
relationship. This is an important question because if there is a causal relationship between 
these conditions, it may be possible to reduce inflammation by alleviating oxidative stress. 
This may be of particular relevance to diseases where chronic inflammation causes tissue 
damage and eventual loss of function.  There are certainly some diseases where increases in 
oxidative stress seem to contribute to the pathology, rather than being merely a 
consequence of increased levels of inflammation. Some of these conditions are discussed 
below with a focus on conditions where reducing oxidative stress has been demonstrated to 
ameliorate the symptoms of disease either in appropriate animal models or in humans. 
 
9.1. Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic autoimmune disease with a worldwide incidence of 
about 1%. Although RA is a systemic disease, it primarily affects synovial joints where 
chronic inflammatory processes can lead to progressive degradation of articular cartilage 
and eventual bone destruction. The exact causes of RA are unknown, but likely involve a 
combination of genetic susceptibility and environmental factors that result in a loss of 
immune tolerance[128]. T cells, B cells and over-production of pro-inflammatory cytokines 
play key roles in the pathogenesis of RA[129].  
Many studies have indicated that increased levels of ROS occur in RA[130], both in synovial 
fluid [131] and in plasma[132]. However, increases in ROS are only significant if not 
adequately buffered by antioxidant defenses, in which case the result is oxidative stress and 
potential oxidative damage to biological molecules and cells. This is indeed the case in RA, 
where increased oxidative stress is a characteristic of the disease[133-135], and perhaps at 
least partially explained by the lower levels of antioxidants such as GSH, Vitamin C, 
thiols[136-138] and the antioxidant enzyme catalase[136] in these patients.  Furthermore, 
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several studies have demonstrated oxidative damage in tissues and synovial fluid in RA, 
examples of which include lipoperoxidation products[139], oxidative damage of hyaluronic 
acid[140], oxidation of low-density lipoproteins[141] and protein oxidation[142]. 
Furthermore, synovial cells from RA patients show upregulation of the transcription factor 
Nrf2, which is known to be activated in response to oxidative stress and limits cartilage 
destruction in a mouse model of arthritis [143, 144].  
A recent systematic review of the role of oxidative stress in RA concluded that oxidative 
stress is likely to be implicated in the pathogenesis of RA, and may even serve as a 
biomarker of disease, but that no firm conclusions could be made due to the heterogeneity 
of the data [145]. Such heterogeneity of results from a combination of a heterogeneous 
patient population and the inherent problems in accurately measuring biomarkers of 
oxidative stress.   
An important question is whether oxidative stress and the concomitant oxidative damage is 
directly involved in initiating and/or maintaining disease. It is possible that the increases in 
oxidative stress occurring in RA are a result of the inflammatory response that is 
dysregulated and continually active in disease. However, an interesting finding from a 
prospective cohort study is that high levels of antioxidants in healthy individuals were 
protective against the development of RA[146] and at least some studies have reported a 
correlation between disease activity and oxidative stress in RA patients[147], although in 
other studies this relationship did not reach significance[148]. More recently, a strong 
correlation between ROS levels and concentrations of TNF and IL-6 were demonstrated in 
the serum of RA patients [149]. Therefore, the idea of using antioxidants for therapeutic 
purposes in RA is attractive. 
Several studies have tested the hypothesis that antioxidant supplementation could be used 
to therapeutic benefit in RA. Most studies have used measurements of MDA and TAC as 
measures of oxidative stress and concentrations of TNF and/or IL-6 as measures of 
inflammation. Treatment of RA patients with antioxidants such as NAC[150], Vitamins A 
and/or E[151, 152] or CoQ10[153] did reduce the levels of MDA in the blood and in some, 
but not all, cases the levels of TAC. However, in those studies that measured disease activity 
using the DAS28 score, there was no significant change indicating that there was little effect 
of the antioxidant supplementation on clinical disease.  
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Animal models of RA have been used to good effect to elucidate the relationship between 
oxidative stress and the disease process. Arthritis in these models is certainly associated 
with increased oxidative stress, mirroring the human disease, with increases in iNOS and 
MDA and decreased Gpx and SOD activity in the affected joints [154]. Intriguingly, local 
overexpression of antioxidant enzymes (SOD3 or catalase) ameliorated arthritis in rats with 
antigen-induced arthritis[155] or mice with collagen-induced arthritis[156] suggesting that 
oxidative stress is directly involved in the pathogenesis of disease. The mechanisms involved 
are less easy to understand. The pro-inflammatory cytokines TNF and IL-6 are key mediators 
of inflammation in RA, but the concentrations of the cytokines were not affected by the 
increased SOD3 or catalase. The protective effects of the antioxidant enzymes were instead 
due to decreases in catabolic enzymes such as matrix metalloproteinases that are up-
regulated in joints affected by arthritis. The decrease in clinical score was thus a result of 
decreased matrix and cartilage degradation rather than inhibiting inflammation[155].  It is 
also important to note that the most successful outcomes on disease activity in rodents 
were achieved by local overexpression of antioxidant enzymes via gene transfer, an 
approach not yet possible in humans. Local reduction of ROS and oxidative stress in the 
effected joints may be necessary for therapeutic effects in RA which would explain why the 
clinical trials described above where systemic administration of antioxidants had little effect 
on disease activity.  
 
9.2. Gout 
Gout is an inflammatory arthritis driven by the production of the pro-inflammatory cytokine, 
IL-1β. It has a worldwide prevalence of 0.1-10 %[157] and is characterized by episodes of 
acute inflammation generated in response to monosodium urate (MSU) deposits in synovial 
joints. Uric acid is the major antioxidant in the blood, contributing around 60% of the free 
radical scavenging capacity[158]. During periods of hyperuricemia, when the concentration 
of serum uric acid increases, crystals of uric acid form and are deposited in synovial joints. It 
is these crystals that are recognized by innate immune cells and result in activation of the 
NLRP3 inflammasome that processes pro-IL-1β for secretion. The inflammation associated 
with an acute gout attack is driven primarily by secreted IL-1β[159].  
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Interestingly, although the greatest risk factor for gout is hyperuricemia, itself an 
antioxidant, gout is associated with increased oxidative stress as indicated by higher MDA 
levels and lower SOD and catalase activities compared with healthy controls[160].  At a 
cellular level, MSU crystals induce the production of ROS in human synoviocytes [161] and 
monocytes [88]. This ability of MSU crystals to induce ROS production is significant as ROS 
have been postulated to be involved in activation of NLRP3 which is necessary for secretion 
of IL-1β. However, as discussed above, this relationship between ROS levels and activation 
of NLRP3 is still unclear.  
The front-line treatment for gout attacks is allopurinol which inhibits the activity of the 
enzyme xanthine oxidase thereby preventing the production of uric acid from xanthine. 
Interestingly, allopurinol treatment also decreases oxidative stress in gout patients, possibly 
by reducing the production of ROS from the xanthine oxidase reaction[160]. However, it is 
difficult to fully elucidate the pathological importance of oxidative stress in gout. Allopurinol 
is therapeutic presumably by lowering uric acid levels and possibly by decreasing oxidative 
stress, but it is difficult to ascertain the relative contributions of these actions to the 
therapeutic benefit.  
 
9.3. Multiple sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) 
that affects approximately 2.5 million people worldwide. Disease is characterised by 
relapsing-remitting episodes following peripheral immune attack on the CNS. This causes 
inflammation in the grey and white matter of the CNS leading to destruction of myelin in the 
brain and spinal cord. Demyelination and persistent glial cell-mediated neuroinflammation 
within the CNS contributes to the accumulation of progressive neurodegeneration and 
disability[162].  
A large and convincing body of literature exists on the importance of oxidative stress in MS 
pathophysiology.  MS is particularly interesting in this regard because oxidative stress appears 
to be a fundamental and possibly causative element of disease as opposed to being a by-
product of inflammation as may be the case in other diseases. There are multiple accounts of 
increased oxidative stress in MS patients, both in the CNS [163-166] and the periphery [167-
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170].  Markers of oxidative damage in MS brain tissue include oxidative damage to cellular 
membrane lipids[166], generation of peroxynitrite which damages proteins and oxidative 
damage to nucleic acids by the formation of 8-hydroxy-2’-deoxyguanosine[171]. 
Furthermore, chronically-activated microglial cells produce reactive oxygen species (ROS) 
that can influence mitochondrial function and energy metabolism that can then result in 
autoimmune-independent neurodegeneration [172].  
It is interesting that a number of antioxidant enzymes such as superoxide dismutase (SOD), 
catalase, haem-oxygenase [166] and peroxiredoxins 2[173] and 6[174] are upregulated in MS, 
probably as a result of chronic oxidative stress. Peroxiredoxin 6 not only protected against 
inflammation in a mouse model of MS, but also against disruption of the blood brain barrier 
by inhibiting the activity of MMP9[174], similar to the ability of catalase and SOD3 to reduce 
cartilage degradation in a mouse model of RA by inhibiting MMPs[155]. Indeed, antioxidant 
enzymes have been tested in animal models of experimental optic neuritis [175-177] or MS 
i.e. experimental autoimmune encephalomyelitis (EAE)[174, 178] for therapeutic effects and 
have been shown to ameliorate the symptoms of disease. Unsurprisingly, a combination of 
antioxidant enzymes (e.g. SOD and catalase) was more effective in reducing the clinical signs 
of EAE than either enzyme alone [177]. Notably, all of these effects of antioxidant enzymes 
that have been studied in vivo have relied on the generation of transgenic mice or 
overexpression of enzymes via gene therapy with adenoviral vectors or engineered syngeneic 
cells[155].  Although these approaches are very useful for proof-of-concept testing in animal 
models, they are not yet appropriate for treating human disease.   
However, the importance of oxidative stress in MS and the potential therapeutic benefits of 
reducing this  is underlined by the fact that one of the front-line treatments for MS, dimethyl 
fumarate (DMF) exerts therapeutic effects at least partially by reducing oxidative stress via 
activation of Nrf2[179, 180]. Furthermore, dietary intake of exogenous antioxidants such as 
flavonoids and α-lipoic acid reduce the clinical signs of disease in animal models of MS[181, 
182] and there is now substantial interest in the use of oral antioxidants for improving the 





The studies summarized in this review clearly indicate that redox modifications are involved 
in the regulation of innate immunity and inflammation. This highlights the role of 
endogenous ROS and redox reactions in regulating immune processes, indicating that use of 
broad-spectrum ROS scavengers may affect important signaling pathways. It should be 
mentioned that, so far, no specific antioxidant molecule has been approved for clinical use 
in any of the inflammatory diseases mentioned in this review, and there were no relevant 
Cochrane reviews available at the time of writing. On the other hand, two Cochrane reviews 
on the use of antioxidants in two acute inflammatory conditions (acute respiratory distress 
syndrome and systemic inflammatory response syndrome) did not recommend their 
therapeutic use [184, 185]. Even the assumption that the pharmacological action of DMF in 
MS is mediated by activation of Nrf2 has been challenged by a study showing its 
effectiveness in a model of MS in Nfr2-knockout mice [186]. 
Nonetheless, there is strong evidence that oxidative stress may in fact occur in several 
inflammatory diseases and it is possible that it may represent a druggable target for at least 
some of them. However, in view of the literature discussed in this review, it is probable that 
decimating ROS levels with antioxidant scavengers may result in several non-specific effects, 
and current studies point to the necessity for more targeted strategies such as specific 
inhibition of ROS-producing enzymes involved in disease that would leave the other ROS-
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